Cullinan Oncology

Cullinan Oncology is one of the...

• Russell 3000.

Cullinan Oncology is a company listed under the stock ticker CGEM (US).

View the org chart displaying its 25 main executives

Most searched biographies at Cullinan Oncology

• Nadim Ahmed, Chief Executive Officer and Director
• David Ryan, Director
• Tony Rosenberg, Director

Popular executive movements at Cullinan Oncology

• Mary Fenton has joined the company as Chief Financial Officer  (posted on April 30 2024).

Create your alert
to follow the executive moves at Cullinan Oncology.

Cullinan Oncology has 2,285 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Karius has just announced a $100 Million fundraising (posted on May 3 2024).
• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
• WindRose Health Investors has announced the acquisition of SubjectWell  (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by Cullinan Oncology

• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Cullinan Oncology, Inc.
• Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference | Cullinan Oncology, Inc.
• Cullinan Oncology to Participate in William Blair Biotech Focus Conference | Cullinan Oncology, Inc.
• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Cullinan Oncology, Inc.
• Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 | Cullinan Oncology, Inc.
• Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Cullinan Oncology, Inc.
• Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting | Cullinan Oncology, Inc.
• Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting | Cullinan Oncology, Inc.
• Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference | Cullinan Oncology, Inc.
• Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results | Cullinan Oncology, Inc.
• View more press releases Close

Social media about Cullinan Oncology

• Cullinan Oncology on Wikipedia, Google News & Yahoo Finance
• Cullinan Oncology on LinkedIn, Twitter & YouTube

Contact by email its executives including Nadim Ahmed

Call Cullinan Oncology at +1 617...

View the org chart

Register to receive your alert

Report an error